
    
      This is a Phase II randomized single blind safety and efficacy study of TOL-463, administered
      to female adults to treat vaginitis. Participants will be randomly assigned (1:1) to dose
      TOL-463 Gel or TOL-463 Insert. Study medication will be administered vaginally, once nightly
      for seven days. The duration of the study for each participant will be approximately 21-30
      days.
    
  